# OnCo record sacituzumab-tirumotecan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sacituzumab-tirumotecan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sacituzumab-tirumotecan" ;
  schema:name "Sacituzumab tirumotecan"@en ;
  schema:description "Sacituzumab tirumotecan is Kelun-Biotech's TROP2 ADC, approved in China in 2024 for pretreated triple-negative breast cancer and then EGFR-mutant lung cancer. Merck holds rights outside Greater China and runs the TroFuse programme of more than ten phase 3 trials across breast, lung, endometrial and cervical cancer; in the US it holds a priority voucher but no approval yet."@en ;
  schema:url <https://onco.cc/drugs/sacituzumab-tirumotecan/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.frontiersin.org/journals/oncology-reviews/articles/10.3389/or.2026.1781533/full> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  onco:approval "China 2024: Pretreated advanced TNBC; later EGFR-mutant NSCLC after TKI" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/cervical/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/trop2/> ;
  onco:companies <https://onco.cc/companies/kelun-biotech/>, <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/t030/>, <https://onco.cc/terms/hydrophilic-next-gen/> ;
  onco:trials <https://onco.cc/trials/nct06670196/>, <https://onco.cc/trials/nct06305754/>, <https://onco.cc/trials/nct06448312/>, <https://onco.cc/trials/nct07216703/>, <https://onco.cc/trials/nct07318558/>, <https://onco.cc/trials/nct06824467/>, <https://onco.cc/trials/nct06356311/>, <https://onco.cc/trials/nct06170788/>, <https://onco.cc/trials/nct06459180/>, <https://onco.cc/trials/nct06422143/>, <https://onco.cc/trials/nct06711900/>, <https://onco.cc/trials/nct06312137/>, <https://onco.cc/trials/nct06952504/>, <https://onco.cc/trials/nct06132958/>, <https://onco.cc/trials/nct05870319/>, <https://onco.cc/trials/nct06074588/>, <https://onco.cc/trials/nct04152499/>, <https://onco.cc/trials/nct05351788/>, <https://onco.cc/trials/nct05816252/>, <https://onco.cc/trials/nct07329322/>, <https://onco.cc/trials/nct06428409/>, <https://onco.cc/trials/nct06483334/>, <https://onco.cc/trials/nct06393374/>, <https://onco.cc/trials/nct06469944/>, <https://onco.cc/trials/nct07252739/>, <https://onco.cc/trials/nct06312176/>, <https://onco.cc/trials/nct07419295/>, <https://onco.cc/trials/nct06966700/>, <https://onco.cc/trials/nct07286149/>, <https://onco.cc/trials/nct05319730/>, <https://onco.cc/trials/nct06637423/>, <https://onco.cc/trials/nct07324629/>, <https://onco.cc/trials/nct06780111/>, <https://onco.cc/trials/nct06445972/>, <https://onco.cc/trials/nct06788912/>, <https://onco.cc/trials/nct06841354/> .